Last-Resort drug opens for kids with rare, deadly cholesterol disease
NCT ID NCT06500598
First seen Oct 31, 2025 · Last updated May 26, 2026 · Updated 23 times
Summary
This program offers evinacumab to children and adults with severe inherited cholesterol or triglyceride conditions who have run out of treatment options. The goal is to lower dangerously high lipid levels and reduce the risk of heart attacks or pancreatitis. Participants receive the drug under close monitoring, but this is not a cure—they will need ongoing treatment to manage their condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.